RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Epidermolysis Bullosa: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
EGFR activity governs stage-dependent fibrotic responses in recessive dystrophic epidermolysis bullosa.
Hang Bing et al., The Journal of investigative dermatology (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42887697/
- 2.
Clitocine for Translational Readthrough in Junctional Epidermolysis Bullosa.
Zhang Rui et al., Matrix biology : journal of the International Society for Matrix Biology (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42874790/
- 3.
Pharmacoeconomic analysis of therapy for dystrophic and junctional types of inherited epidermolysis bullosa
Sergey Kensarinovich Zyryanov et al., Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice (12 October 2026)
https://doi.org/10.37489/2588-0519-gcp-0036
- 4.
Beremagene geperpavec (B-VEC): the first topical gene therapy for dystrophic epidermolysis bullosa
Emily Wang et al., Archives of Dermatological Research (9 October 2026)
https://doi.org/10.1007/s00403-026-04864-5
- 5.
Severe Ocular Surface Disease In A Pediatric Patient With Recessive Dystrophic Epidermolysis Bullosa: A Clinical Case
Pedro Mota-Moreira et al., ESCRS Abstracts (9 October 2026)
https://doi.org/10.82333/e04v-hf70
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132 · Active (not recruiting) · Phase 2 / Phase 3 · TWi Biotechnology, Inc.
Ages 6 Months and over
https://clinicaltrials.gov/study/NCT06073132
- 2.
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
NCT03154333 · TERMINATED · Phase 2 · Castle Creek Pharmaceuticals, LLC
Ages 4 and over
https://clinicaltrials.gov/study/NCT03154333
- 3.
Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
NCT03068780 · Completed · Phase 3 · Amryt Research Limited
Ages 21 Days and over
https://clinicaltrials.gov/study/NCT03068780
- 4.
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
NCT03016715 · UNKNOWN · Phase 2 · Premier Specialists, Australia
Ages 5 and over
https://clinicaltrials.gov/study/NCT03016715
- 5.
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
NCT02670330 · TERMINATED · Phase 3 · Scioderm, Inc.
Ages 1 Month and over
https://clinicaltrials.gov/study/NCT02670330
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Epidermolysis Bullosa
Epidermolysis bullosa is a group of rare genetic conditions that cause extremely fragile skin that blisters and tears easily. It affects the proteins that anchor skin layers together. Severity ranges from mild to life-threatening. Gene therapy and advanced wound care are transforming treatment.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Repeated injury can impair transitions between cellular phenotypes, potentially leading to pathological tissue repair. In recessive dystrophic epidermolysis bullosa (RDEB), collagen VII deficiency predisposes to repeated tissue injury, driving inflammation and fibrosis. Although fibroblasts are major effector cells in RDEB fibrosis, their phenotypic and molecular changes underlying disease progression remain elusive. Through cellular and in situ analyses of clinical samples and tissue from an RDEB mouse model, we disclose a phenotypic switch in dermal fibroblasts during disease progression. At early stages, fibroblasts display a contractile phenotype, whereas at later stages they transition toward a less contractile phenotype with increased production of a fibrosis-promoting extracellular matrix, indicated by high tenascin-C levels. Dysregulated epidermal growth factor receptor (EGFR) signaling through AKT appears central to this switch. At early stages, EGFR signaling and AKT support fibroblast contractility, whereas at later stages this signaling becomes intrinsically blunted, with ADAM17 implicated in the transition. The type of inflammation modulates this phenotypic switch. Thus, RDEB fibroblasts transition from a contractile to a less contractile but pro-fibrotic phenotype during disease progression. These findings suggest that reducing cellular contractility may be advantageous at earlier disease stages, whereas extracellular matrix-targeting strategies may have higher priority at later stages.
Common Questions
What is Epidermolysis Bullosa?
Epidermolysis bullosa is a group of rare genetic conditions that cause extremely fragile skin that blisters and tears easily. It affects the proteins that anchor skin layers together. Severity ranges from mild to life-threatening. Gene therapy and advanced wound care are transforming treatment.
How many clinical trials are available for Epidermolysis Bullosa?
RareWays currently indexes 117 clinical trials for Epidermolysis Bullosa, of which 13 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Epidermolysis Bullosa come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Epidermolysis Bullosa.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.